- Home
- NIE vs AUTL Comparison
NIE vs AUTL Comparison
Compare NIE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- AUTL
- Stock Information
- Founded
- NIE 2007
- AUTL 2014
- Country
- NIE United States
- AUTL United Kingdom
- Employees
- NIE N/A
- AUTL N/A
- Industry
- NIE Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIE Finance
- AUTL Health Care
- Exchange
- NIE Nasdaq
- AUTL Nasdaq
- Market Cap
- NIE 691.6M
- AUTL 625.4M
- IPO Year
- NIE N/A
- AUTL 2018
- Fundamental
- Price
- NIE $24.72
- AUTL $1.27
- Analyst Decision
- NIE
- AUTL Strong Buy
- Analyst Count
- NIE 0
- AUTL 5
- Target Price
- NIE N/A
- AUTL $9.12
- AVG Volume (30 Days)
- NIE 70.5K
- AUTL 4.4M
- Earning Date
- NIE 01-01-0001
- AUTL 11-11-2025
- Dividend Yield
- NIE 9.04%
- AUTL N/A
- EPS Growth
- NIE N/A
- AUTL N/A
- EPS
- NIE N/A
- AUTL N/A
- Revenue
- NIE N/A
- AUTL $29,934,000.00
- Revenue This Year
- NIE N/A
- AUTL $641.63
- Revenue Next Year
- NIE N/A
- AUTL $109.21
- P/E Ratio
- NIE N/A
- AUTL N/A
- Revenue Growth
- NIE N/A
- AUTL 185.17
- 52 Week Low
- NIE $18.61
- AUTL $1.11
- 52 Week High
- NIE $22.47
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- NIE 50.70
- AUTL 24.20
- Support Level
- NIE $24.83
- AUTL $1.30
- Resistance Level
- NIE $25.10
- AUTL $1.46
- Average True Range (ATR)
- NIE 0.20
- AUTL 0.09
- MACD
- NIE -0.04
- AUTL 0.01
- Stochastic Oscillator
- NIE 21.26
- AUTL 2.63
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.